Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III Report

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Use of plant stanols/sterols in forms that are sufficiently bioavailable for therapeutic effect should be a key element of maximal dietary therapy. This principle was recognized by National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and has been amply confirmed by experimental studies in humans. Since the introduction of statins, dietary therapy for control of elevated low-density lipoprotein (LDL) cholesterol levels has received less attention. The time has come, however, to reassert the importance of maximal dietary therapy as a cost-effective means for treatment of elevated LDL concentrations and for lifetime prevention of coronary heart disease.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume96
Issue number1 SUPPL.
DOIs
StatePublished - Jul 4 2005

Fingerprint

Esters
Cholesterol
Education
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Phytosterols
Therapeutic Uses
LDL Lipoproteins
LDL Cholesterol
Coronary Disease
Therapeutics
Costs and Cost Analysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{907b5f5f5469468e862518048ef87767,
title = "Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III Report",
abstract = "Use of plant stanols/sterols in forms that are sufficiently bioavailable for therapeutic effect should be a key element of maximal dietary therapy. This principle was recognized by National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and has been amply confirmed by experimental studies in humans. Since the introduction of statins, dietary therapy for control of elevated low-density lipoprotein (LDL) cholesterol levels has received less attention. The time has come, however, to reassert the importance of maximal dietary therapy as a cost-effective means for treatment of elevated LDL concentrations and for lifetime prevention of coronary heart disease.",
author = "Grundy, {Scott M}",
year = "2005",
month = "7",
day = "4",
doi = "10.1016/j.amjcard.2005.03.020",
language = "English (US)",
volume = "96",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III Report

AU - Grundy, Scott M

PY - 2005/7/4

Y1 - 2005/7/4

N2 - Use of plant stanols/sterols in forms that are sufficiently bioavailable for therapeutic effect should be a key element of maximal dietary therapy. This principle was recognized by National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and has been amply confirmed by experimental studies in humans. Since the introduction of statins, dietary therapy for control of elevated low-density lipoprotein (LDL) cholesterol levels has received less attention. The time has come, however, to reassert the importance of maximal dietary therapy as a cost-effective means for treatment of elevated LDL concentrations and for lifetime prevention of coronary heart disease.

AB - Use of plant stanols/sterols in forms that are sufficiently bioavailable for therapeutic effect should be a key element of maximal dietary therapy. This principle was recognized by National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and has been amply confirmed by experimental studies in humans. Since the introduction of statins, dietary therapy for control of elevated low-density lipoprotein (LDL) cholesterol levels has received less attention. The time has come, however, to reassert the importance of maximal dietary therapy as a cost-effective means for treatment of elevated LDL concentrations and for lifetime prevention of coronary heart disease.

UR - http://www.scopus.com/inward/record.url?scp=21244485459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244485459&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.03.020

DO - 10.1016/j.amjcard.2005.03.020

M3 - Article

C2 - 15992516

AN - SCOPUS:21244485459

VL - 96

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1 SUPPL.

ER -